Cochlear (COH) Stock Price, Fundamentals & Analysis

What COH does

Cochlear (COH) is a stock listed on the ASX in the Healthcare sector, Medical Devices industry. The company provides implantable hearing solutions, including cochlear implant systems, replacement sound processors, bone conduction systems, and recipient support tools. It also offers connected care solutions such as the Cochlear Nucleus SmartNav System, Cochlear Custom Sound Pro Fitting Software, Cochlear Remote Assist, Cochlear Remote Check, and Cochlear Link. Products are sold under the Cochlear, Nucleus, Nexa, Osia, and Cochlear Baha brands across the Americas, Europe, the Middle East, Africa, and Asia Pacific.

Key numbers explained

• Price (142.3 AUD): the most recent trading price of one share on the ASX.
• Trailing P/E ratio (63.2): current price divided by last 12 months' earnings per share (2.25 AUD); a higher number can mean the market expects strong future growth.
• Forward P/E ratio (24.7): price divided by expected future earnings; often easier to compare across companies than the trailing figure.
• Dividend yield (1.83%): annual dividend as a percentage of the current price; the exDividendDate is Sep 21, 2026.
• Share of earnings paid out as dividends (191%): the company is paying out more in dividends than it earns in the trailing period, often funded by past savings or borrowing.
• Beta (0.27): a measure of share price sensitivity to the overall market; below 1 suggests lower volatility than the market average.
• 52-week range: 88.74 (low) to 296.5 (high); the price is currently -49% from a year ago.
• Debt-to-equity ratio (12.2%): total debt as a percentage of shareholders' equity; a low figure suggests a conservative capital structure.

What to watch

Cochlear operates in a regulated healthcare environment where product approvals, reimbursement policies, and clinical evidence can affect demand. As a medical device company with global sales, currency movements and supply-chain conditions are relevant. Earnings releases, typically around the nextEarningsDate (Aug 18, 2026), and updates on R&D pipelines can drive short-term price moves. Investors often compare COH with peers such as Fisher & Paykel Healthcare (FPH) or Sigma Healthcare (SIG) to contextualise valuation and growth.